NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY

Медицинский совет

S. N. AVDEEV¹ 

[1] Scientific and Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia;

关键词: copd;    bronchodilators;    fixed combination s;    long-acting anticholinergics;    long-acting β2-agonists;    indacaterol;    glycopyrronium bromide;   

DOI  :  10.21518/2079-701X-2016-15-11-16

来源: DOAJ

【 摘 要 】

The therapy by fixed combinations, LABA/LAACD on the basis of indacaterol and glycopyrronium bromide is characterized by a high clinical efficacy compared to monocomponents of the product, tiotropium, and a fixed combination of LABA/iCGS. The results of the clinical studies confirm the pharmacological concept of synergistic potentiation of the bronchodilator effect by using medications with different mechanisms of action, which LABA and LAACD are. It is important that the achievement of additional therapeutic effect is possible without increasing the risk of adverse effects. All this is the basis for the conclusion that the joint indication of indacaterol and glycopyrrolate can lead to optimization and maximization of bronchodilatation of many COPD patients who didn’t achieve adequate improvement of bronchial patency with the use of only one bronchodilator. Combination therapy with indacaterol and glycopyrronium (drug Ultipro® Brizhaler®, Novartis Pharma) results in significant improvement of clinical symptoms, pulmonary function, quality of life and decrease of exacerbations in patients with COPD.

【 授权许可】

Unknown